Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials.

Literature DB >> 28255021

No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials.

Tiziano Barbui¹, Alessandra Carobbio², Arianna Ghirardi², Arianna Masciulli², Alessandro Rambaldi^3,4, Alessandro M Vannucchi⁵.

Abstract

Entities: Chemical Disease

Mesh：

Year: 2017 PMID： 28255021 PMCID： PMC5451347 DOI： 10.3324/haematol.2017.165126

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

10 in total

1. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors: A M Vannucchi; T Barbui; F Cervantes; C Harrison; J-J Kiladjian; N Kröger; J Thiele; C Buske
Journal: Ann Oncol Date: 2015-08-04 Impact factor: 32.976

2. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.

Authors: Jean-Jacques Kiladjian; Bruno Cassinat; Sylvie Chevret; Pascal Turlure; Nathalie Cambier; Murielle Roussel; Sylvia Bellucci; Bernard Grandchamp; Christine Chomienne; Pierre Fenaux
Journal: Blood Date: 2008-07-23 Impact factor: 22.113

3. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.

Authors: Tiziano Barbui; Giovanni Barosi; Gunnar Birgegard; Francisco Cervantes; Guido Finazzi; Martin Griesshammer; Claire Harrison; Hans Carl Hasselbalch; Rudiger Hehlmann; Ronald Hoffman; Jean-Jacques Kiladjian; Nicolaus Kröger; Ruben Mesa; Mary F McMullin; Animesh Pardanani; Francesco Passamonti; Alessandro M Vannucchi; Andreas Reiter; Richard T Silver; Srdan Verstovsek; Ayalew Tefferi
Journal: J Clin Oncol Date: 2011-01-04 Impact factor: 44.544

4. Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

Authors: Alessandro M Vannucchi; Jean Jacques Kiladjian; Martin Griesshammer; Tamas Masszi; Simon Durrant; Francesco Passamonti; Claire N Harrison; Fabrizio Pane; Pierre Zachee; Ruben Mesa; Shui He; Mark M Jones; William Garrett; Jingjin Li; Ulrich Pirron; Dany Habr; Srdan Verstovsek
Journal: N Engl J Med Date: 2015-01-29 Impact factor: 91.245

5. Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera.

Authors: A P Tartaglia; J D Goldberg; P D Berk; L R Wasserman
Journal: Semin Hematol Date: 1986-07 Impact factor: 3.851

6. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.

Authors: Francesco Passamonti; Martin Griesshammer; Francesca Palandri; Miklos Egyed; Giulia Benevolo; Timothy Devos; Jeannie Callum; Alessandro M Vannucchi; Serdar Sivgin; Caroline Bensasson; Mahmudul Khan; Nadjat Mounedji; Guray Saydam
Journal: Lancet Oncol Date: 2016-12-02 Impact factor: 41.316

7. Cardiovascular events and intensity of treatment in polycythemia vera.

Authors: Roberto Marchioli; Guido Finazzi; Giorgina Specchia; Rossella Cacciola; Riccardo Cavazzina; Daniela Cilloni; Valerio De Stefano; Elena Elli; Alessandra Iurlo; Roberto Latagliata; Francesca Lunghi; Monia Lunghi; Rosa Maria Marfisi; Pellegrino Musto; Arianna Masciulli; Caterina Musolino; Nicola Cascavilla; Giovanni Quarta; Maria Luigia Randi; Davide Rapezzi; Marco Ruggeri; Elisa Rumi; Anna Rita Scortechini; Simone Santini; Marco Scarano; Sergio Siragusa; Antonio Spadea; Alessia Tieghi; Emanuele Angelucci; Giuseppe Visani; Alessandro Maria Vannucchi; Tiziano Barbui
Journal: N Engl J Med Date: 2012-12-08 Impact factor: 91.245

8. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea.

Authors: Alberto Alvarez-Larrán; Manuel Pérez-Encinas; Francisca Ferrer-Marín; Juan Carlos Hernández-Boluda; María José Ramírez; Joaquín Martínez-López; Elena Magro; Yasmina Cruz; María Isabel Mata; Pilar Aragües; María Laura Fox; Beatriz Cuevas; Sara Montesdeoca; José Angel Hernández-Rivas; Valentín García-Gutiérrez; María Teresa Gómez-Casares; Juan Luis Steegmann; María Antonia Durán; Montse Gómez; Ana Kerguelen; Abelardo Bárez; Mari Carmen García; Concepción Boqué; José María Raya; Clara Martínez; Manuel Albors; Francesc García; Carmen Burgaleta; Carlos Besses
Journal: Haematologica Date: 2016-09-29 Impact factor: 9.941

9. Efficacy and safety of low-dose aspirin in polycythemia vera.

Authors: Raffaele Landolfi; Roberto Marchioli; Jack Kutti; Heinz Gisslinger; Gianni Tognoni; Carlo Patrono; Tiziano Barbui
Journal: N Engl J Med Date: 2004-01-08 Impact factor: 91.245

10. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.

Authors: P D Berk; J D Goldberg; P B Donovan; S M Fruchtman; N I Berlin; L R Wasserman
Journal: Semin Hematol Date: 1986-04 Impact factor: 3.851

10 in total

7 in total

Review 1. What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?

Authors: Alessandro M Vannucchi; Paola Guglielmelli
Journal: Hematology Am Soc Hematol Educ Program Date: 2017-12-08

2. The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera.

Authors: Nikolai A Podoltsev; Mengxin Zhu; Amer M Zeidan; Rong Wang; Xiaoyi Wang; Amy J Davidoff; Scott F Huntington; Smith Giri; Steven D Gore; Xiaomei Ma
Journal: Blood Adv Date: 2018-10-23

6. Hydralazine Associated With Reduced Therapeutic Phlebotomy Frequency in a Nationwide Cohort Study: Real-World Effectiveness for Drug Repurposing.

Authors: Wei-Zhi Lin; Chi-Hsiang Chung; Chia-Yang Shaiu; Bing-Heng Yang; Wu-Chien Chien
Journal: Front Pharmacol Date: 2022-04-01 Impact factor: 5.988

Review 7. Advances in the Treatment of Polycythemia Vera: Trends in Disease Management.

Authors: Yajur Arya; Arshi Syal; Monica Gupta; Saurabh Gaba
Journal: Cureus Date: 2021-03-30